Press Release

Mergers and Strategic Alliances Paving New Opportunities for DNA Damage Response Drug Market

With the changing lifestyle, and environmental impacts the human DNA is undergoing a radical change.  Ionizing radiation are contributing to a greater impact on DNA. The DNA directly absorbs radiation energy and gets damaged. Moreover, DNA damage leads to a combination of defects and aberrations in the genome that often result in functional mutations. When these mutations happen in genes coding for viral proteins and/or enzymes, it leads to the development of genetic diseases. However, the human biological system is equipped with a robust repair mechanism that is capable of correcting damaged DNA sequences. PARP inhibitors and other similar therapeutics are designed to augment the body’s innate DNA repair mechanism and support in the treatment of diseases associated with genetic aberrations. 
 
According to MarkNtel Advisors’ research report “Global DNA Damage Response Drugs Market Analysis, 2020”, the global DNA Damage Response Drugs market is anticipated to growing at a healthy CAGR during 2020-25. Moreover, the market presence of DNA damage response drug is burgeoning due to the mounting cases of skin disorders.

Quick Adoption of PARP Inhibitors
Based on type, the PARP inhibitors gained the largest market share in 2019 and the segment is expected to bolster during the forecast period. PARP inhibitors can inhibit the repair of DNA damage of tumor cells through a synergistic lethal effect, thereby killing tumor cells, which is a safe and effective new treatment method. Currently, a large number of PARP inhibitors with decent selectivity and sensitivity have been developed, where mostly entered the stage of clinical trials. However, PARP inhibitors require precise targets, leading to severe limitations in the use of PARP inhibitors as single agents as revealed by the MarkNtel Advisors’ research report “Global DNA Damage Response Drugs Market Analysis, 2020”.  

Increasing Strategic Alliances to Bolster Research 
Companies are increasing collaborations and mergers for development and advancement of drugs research for instance, in 2019, AstraZeneca has entered into a global development and commercialization collaboration agreement with Daiichi Sankyo Company, Limited (Daiichi Sankyo) for trastuzumab deruxtecan (DS-8201), a proprietary antibody-drug conjugate (ADC) and potential new targeted medicine for cancer treatment. Also, Artios Pharma Limited (Artios), The University of Texas MD Anderson Cancer Center (MD Anderson) and ShangPharma Innovation (ShangPharma) announced the in-licensing by Artios of a small-molecule ATR inhibitor programme, developed jointly by MD Anderson and ShangPharma in the same year.

According to MarkNtel Advisors’, Bristol Myers Squibb, Genentech, British Columbia Cancer Agency, National Health Service, 4SC AG, ARCAGY/GINECO Group, Cambridge University Hospitals NHS Foundation Trust, Georgetown University, KuDOS

Pharmaceuticals, National Institutes of Health are few of the leading players in the Global DNA Damage Response Drugs Market. 
“Global DNA Damage Response Drugs Market Analysis, 2020” provides comprehensive qualitative and quantitative insights on the industry potential, key factors impacting sales and purchase decisions, hotspots, and opportunities available for DNA Damage Response Drugs providers across the Globe. Moreover, the report also encompasses the key strategic imperatives for success for competitors along with strategic factorial indexing measuring competitor's capabilities on 16 parameters. This will help companies in the formulation of Go to Market Strategies and identifying the blue ocean for its offerings.       

Market Segmentation:
1.    By Application (Oncological, Stroke), 
2.    By Type (PAR Inhibitors and others), 
3.    By Region (North America, South America, Europe, Asia-Pacific, Middle East & Africa), 
4.    By Country (US, Canada, Mexico, Brazil, Argentina, Germany, France, UK, Spain, Italy, China, Japan, South Korea, India, Australia, Saudi Arabia, UAE) 
5.    By Company (Bristol Myers Squibb, Genentech, British Columbia Cancer Agency, National Health Service, 4SC AG, ARCAGY/GINECO Group, Cambridge University Hospitals NHS Foundation Trust, Georgetown University, KuDOS Pharmaceuticals, National Institutes of Health)

Key questions answered in the study: 
1.    What are the current and future market trends of the industry? 
2.    How the industry has been evolving in terms of end-user demand and application areas?
3.    How the competition has been shaping across the countries followed by their comparative factorial indexing?
4.    What are the key growth drivers and challenges for the DNA Damage Response Drugs industry?
5.    What are the customer orientation, purchase behavior, and expectations from the DNA Damage Response Drugs firms across various regions?